TABLE 3.
Overview of patients achieving a reduction in MMD at Month 2 or 3 and at Months 2 and 3, based on initial response at Month 1
| Initial response status | N1 | Treatment | |||||
|---|---|---|---|---|---|---|---|
| Subsequent response at Month 2 or 3, n (%) | Subsequent response at Months 2 and 3, n (%) | ||||||
| Partial | Good or better | Excellent | Partial | Good or better | Excellent | ||
| Erenumab 70 mg (N = 188) | |||||||
| Good or better | 45 | 3 (6.7) | 38 (84.4) | 25 (55.6) | 11 (24.4) | 22 (48.9) | 8 (17.8) |
| Partial | 45 | 5 (11.1) | 29 (64.4) | 8 (17.8) | 12 (26.7) | 15 (33.3) | 4 (8.9) |
| Limited | 70 | 15 (21.4) | 30 (42.9) | 9 (12.9) | 16 (22.9) | 8 (11.4) | 3 (4.3) |
| No change or worsening | 28 | 2 (7.1) | 4 (14.3) | 2 (7.1) | 1 (3.6) | 2 (7.1) | 0 |
| Erenumab 140 mg (N = 187) | |||||||
| Good or better | 53 | 3 (5.7) | 48 (90.6) | 31 (58.5) | 6 (11.3) | 37 (69.8) | 17 (32.1) |
| Partial | 34 | 3 (8.8) | 27 (79.4) | 10 (29.4) | 11 (32.4) | 12 (35.3) | 4 (11.8) |
| Limited | 67 | 19 (28.4) | 14 (20.9) | 5 (7.5) | 6 (9.0) | 7 (10.4) | 1 (1.5) |
| No change or worsening | 33 | 12 (36.4) | 7 (21.2) | 0 | 6 (18.2) | 0 | 0 |
Abbreviations: MMD, monthly migraine day; %, n/N1.